MOTS-c vs Tesamorelin
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA that acts on skeletal muscle metabolism through AMPK, while tesamorelin is a 44-amino-acid analogue of growth hormone-releasing hormone that signals the pituitary to release growth hormone. Both turn up in body-composition research, but they work at opposite ends of the body: one inside muscle cells, the other through the brain’s hormone axis. Tesamorelin has large randomised human trials and approval as a medicine in the United States; MOTS-c’s human data so far measure the body’s own levels. Here is how they compare.
Findings
- MOTS-c inhibits the folate cycle, activates AMPK and prevented diet-induced obesity and insulin resistance in mice; its main target organ appears to be skeletal muscle (2015).
- Tesamorelin is the 44-amino-acid sequence of human GHRH with a hexenoyl group on the N-terminal tyrosine, and binds GHRH receptors with potency similar to the natural hormone (US prescribing information).
- In a 26-week trial in 412 people with HIV and abdominal fat, tesamorelin cut visceral fat 15.2% while placebo rose 5.0%, and IGF-1 rose 81% (2007).
- In sedentary young men, exercise raised muscle MOTS-c 11.9-fold; in mice, MOTS-c treatment improved running capacity at every age tested (2021).
What is MOTS-c?
MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide coded inside the mitochondrial 12S rRNA gene. Its cellular action inhibits the folate cycle and the de novo purine synthesis tied to it, leading to AMPK activation, and its primary target organ appears to be skeletal muscle. In mice it prevented age-dependent and high-fat-diet-induced insulin resistance as well as diet-induced obesity (Lee et al., Cell Metab, 2015). Under stress it moves into the nucleus and regulates nuclear genes, including those for metabolism and proteostasis (Reynolds et al., Nat Commun, 2021). The basics are in What Is MOTS-c?
The research
MOTS-c improved physical performance in young (2-month), middle-aged (12-month) and old (22-month) mice; two weeks of treatment let the old mice run about twice as long on a treadmill, and treatment begun late in life improved physical capacity and healthspan (Reynolds et al., 2021). The same paper found that in sedentary young men cycling, muscle MOTS-c rose 11.9-fold after exercise and blood MOTS-c rose 1.6-fold during it.
Circulating MOTS-c was lower in older men than in young men, though muscle levels were about 1.5-fold higher in the middle-aged and older groups (D’Souza et al., Aging, 2020). In 125 adults without diabetes, plasma MOTS-c was higher with metabolic syndrome and was associated with liver fat (Sequeira et al., Biochim Biophys Acta Gen Subj, 2021). These human studies measure naturally occurring MOTS-c; no controlled trial of MOTS-c given to people has been published. More is in MOTS-c: Exercise, Heat and the Mitochondrial Signal.
What is tesamorelin?
Tesamorelin is a synthetic analogue of growth hormone-releasing factor (GHRH): the full 44-amino-acid human sequence with a six-carbon hexenoyl chain attached to the N-terminal tyrosine. It binds and stimulates human GHRH receptors with potency similar to the natural hormone, prompting the pituitary to make and release growth hormone in its normal pulses, which in turn raises IGF-1. It was first approved in the United States in 2010, as Egrifta, for reducing excess abdominal fat in adults with HIV-associated lipodystrophy; the label describes it as weight neutral and not indicated for weight loss, and gives a mean elimination half-life of 8 minutes (Egrifta SV prescribing information, Theratechnologies, 2026). The structural change is explained in Tesamorelin: One Small Change to a Natural Hormone.
The human trials
In a 26-week randomised, placebo-controlled trial of 412 people with HIV and abdominal fat accumulation, visceral fat fell 15.2% with tesamorelin and rose 5.0% with placebo; triglycerides and the cholesterol ratio improved and IGF-1 rose 81%, with no significant change in glycaemic measures (Falutz et al., N Engl J Med, 2007). A pooled analysis of two phase 3 trials covering 806 patients found visceral fat reductions maintained to 52 weeks, at 17.5% from baseline in those who stayed on tesamorelin, while abdominal subcutaneous fat was preserved (Falutz et al., J Clin Endocrinol Metab, 2010).
Liver fat followed. In a 6-month double-blind trial in 50 patients, tesamorelin reduced both visceral and liver fat (Stanley et al., JAMA, 2014). In a 12-month randomised, double-blind trial in 61 people with HIV and fatty liver, liver fat fell by a relative 37% against placebo, and 35% of the tesamorelin group ended below the 5% fatty-liver threshold, against 4% on placebo (Stanley et al., Lancet HIV, 2019). The full record is in Tesamorelin and Visceral Fat: The Trial Record and Tesamorelin and Liver Fat.
How do MOTS-c and tesamorelin compare side by side?
| Question | MOTS-c | Tesamorelin |
|---|---|---|
| What is it? | Mitochondrial-derived peptide | Synthetic GHRH analogue |
| Size | 16 amino acids | 44 amino acids plus a hexenoyl group |
| Main research area | Insulin sensitivity, exercise capacity, ageing | Visceral fat and liver fat |
| Mechanism | Folate cycle, AICAR, AMPK in muscle | GHRH receptors on the pituitary; GH and IGF-1 |
| Human evidence | Endogenous levels only (exercise, age, liver fat) | Phase 3 RCTs; approved in the US since 2010 |
| Forms we supply | 10 mg and 40 mg vials | 10 mg vial; Tesamorelin + Ipamorelin Stack |
Where do their research areas overlap?
Liver fat and fat distribution. Tesamorelin has controlled trials showing lower visceral and liver fat. MOTS-c’s human link is observational: plasma levels rose with liver fat in the 2021 cohort, which the authors read as part of a stress response, alongside mouse studies in which MOTS-c treatment prevented diet-induced obesity. Tesamorelin works through the growth hormone axis, which the label describes as lipolytic; MOTS-c works within the muscle cell’s own energy sensing. The two literatures therefore describe different routes to related outcomes, not the same effect.
Which one fits which research question?
- Visceral fat, liver fat and the GH/IGF-1 axis: tesamorelin, which has phase 3 trials with CT and MR spectroscopy endpoints.
- Muscle glucose handling, AMPK signalling, exercise capacity and mitochondrial signalling: MOTS-c.
- Ageing: MOTS-c has the late-life mouse healthspan data; tesamorelin’s human trials enrolled adults with HIV rather than ageing cohorts.
Can MOTS-c and tesamorelin be studied together?
Yes. One acts through the pituitary and growth hormone, the other inside muscle through AMPK, so a design using both keeps two distinguishable variables and can measure IGF-1 as a marker specific to tesamorelin. That rationale is built from each compound’s own literature; we found no published study of the pair. Tesamorelin is also compared in CJC-1295 + Ipamorelin vs Tesamorelin and Tesamorelin vs HGH, and MOTS-c in MOTS-c vs SS-31 and 5-Amino-1MQ vs MOTS-c.
How are MOTS-c and tesamorelin supplied?
MOTS-c comes as 10 mg and 40 mg lyophilised vials and is part of the Mitochondrial Energy stack. Tesamorelin comes as a 10 mg lyophilised vial and in the Tesamorelin + Ipamorelin Stack. Vials are reconstituted with bacteriostatic water: see the MOTS-c reconstitution guide and the tesamorelin reconstitution guide. Certificates of analysis are on the lab reports page, and every order ships from within Canada by Canada Post Xpresspost.
MOTS-c and tesamorelin are supplied for laboratory research use only. The tesamorelin trials above used the approved pharmaceutical product; the MOTS-c treatment studies were in mice.
Frequently asked questions
What is the difference between MOTS-c and tesamorelin?
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA that activates AMPK in skeletal muscle. Tesamorelin is a 44-amino-acid GHRH analogue that signals the pituitary to release growth hormone, raising IGF-1. One acts inside muscle cells; the other through the hormone axis.
Is MOTS-c stronger than tesamorelin for fat loss?
They have not been compared. Tesamorelin has randomised human trials in which visceral fat fell 15.2% over 26 weeks while it rose 5.0% on placebo, and trials showing reduced liver fat. MOTS-c prevented diet-induced obesity in mice, but no controlled human trial of MOTS-c has been published.
Is tesamorelin an approved drug?
Yes. Tesamorelin was first approved in the United States in 2010 for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Its label describes it as weight neutral and not indicated for weight loss.
Can MOTS-c and tesamorelin be studied together?
Yes. One works through the pituitary and growth hormone and the other through AMPK in muscle, so a study using both keeps two distinguishable variables. No published study has tested the pair.
Where can I buy MOTS-c and tesamorelin in Canada?
Vistara Labs supplies MOTS-c as 10 mg and 40 mg vials and tesamorelin as a 10 mg vial, plus the Mitochondrial Energy stack and the Tesamorelin + Ipamorelin Stack, shipped from within Canada by Canada Post Xpresspost.
Product details from vistaralabs.ca, October 2026. Sources: Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. PMID 25738459. Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021. PMID 33473109. D’Souza RF et al. Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition. Aging (Albany NY). 2020. PMID 32182209. Sequeira IR et al. Plasma mitochondrial derived peptides MOTS-c and SHLP2 positively associate with android and liver fat in people without diabetes. Biochim Biophys Acta Gen Subj. 2021. PMID 34419510. Egrifta SV (tesamorelin) prescribing information. Theratechnologies Inc. DailyMed. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. PMID 18057338. Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010. PMID 20554713. Stanley TL et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014. PMID 25038357. Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019. PMID 31611038.
More on this: Hormonal, Growth Hormone & Body Composition Research.
All products supplied by Vistara Labs are intended for laboratory research use only. They are not drugs, are not approved for human or veterinary use, and are not intended to diagnose, treat, cure or prevent any condition. Nothing on this page constitutes medical advice or guidance for use in humans.
